Latest advances in treatment strategies for hypereosinophilic syndromes & challenges in this fie

0 Views

07/06/23

Amy Klion, MD, National Institutes of Health (NIH), Bethesda, MD, highlights recent advances in the field of hypereosinophilic syndromes (HES), highlighting some of the challenges in this space. Dr Klion comments on the mechanism of action (MOA) of drugs targeting IL-5 and IL-5Ra and emphasizes the importance of determining the most appropriate drug for each patient and of identifying mutations driving eosinophilia. Dr Klion further comments on novel agents in the field of HES, explaining that further investigation into the long-term safety of these agents is required. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.